Table 2:

Comparison of Baseline Characteristics between SSc-ILD Patients with FVC ≥ 80% predicted and FVC < 80% predicted

		FVC ≥ 80% & ILD N = 43	FVC < 80% & ILD N = 72
Age, mean ± SD years		54.7 ± 11.7	52.1 ± 13.7
Female sex, n (%)		33 (76.7)	41 (56.9)
Race, n (%)
White		36 (83.7)	46 (63.9)
Black		1 (2.3)	20 (27.8)
Asian		4 (9.3)	2 (2.8)
Hispanic ethnicity, n (%)		3 (7.0)	10 (13.9)
Smoking status, n (%)
Never		25 (58.1)	45 (62.5)
Former		16 (37.2)	21 (29.2)
Current		2 (4.7)	6 (8.3)
Disease duration from 1st non-Raynaud’s symptom, mean ± SD years		1.0 ± 0.6	1.4 ± 0.8
Modified Rodnan skin score, mean ± SD		19.1 ± 9.7	20.5 ± 10.0 N = 70
Antinuclear antibody (ANA) positive, n (%)		32 (88.9) N = 36	57 (91.9) N = 62
Anti-topoisomerase I positive, n (%)		13 (37.1) N = 35	27 (43.5) N = 62
Anti-RNA polymerase III positive, n (%)		17 (53.1) N = 32	20 (37.7) N = 53
Anti-centromere positive, n (%)		0 (0) N = 32	1 (1.9) N = 53
FVC, mean ± SD liters		3.4 ± 0.8	2.6 ± 0.7 N = 71
FVC, mean ± SD % predicted		96.8 ± 9.6	63.7 ± 9.6
FEV1, mean ± SD liters		4.6 ± 12.6	2.1 ± 0.6 N = 70
FEV1, mean ± SD % predicted		95.2 ± 17.9	69.7 ± 11.8 N = 71
FEV1/FVC ratio, mean ± SD		80.1 ± 8.5 N = 41	88.5 ± 11.7 N = 66
TLC, mean ± SD liters		5.3 ± 1.0 N = 36	4.1 ± 1.0 N = 49
TLC, mean ± SD % predicted		102.0 ± 12.3 N = 36	70.1 ± 13.0 N = 49
DLCO, mean ± SD % predicted		74.8 ± 20.3 N = 42	51.5 ± 18.4 N = 67
New York Heart Association Functional Class, n (%)		N = 41	N = 66
I		21 (51.2)	22 (33.3)
II		16 (39.0)	28 (42.4)
III		4 (9.8)	16 (24.2)
IV		0 (0)	0 (0)
SHAQ breathlessness score, mean ± SD		1.6 ± 2.2 N = 35	3.1 ± 3.3 N = 59

SSc = systemic sclerosis; ILD = interstitial lung disease; FVC = forced vital capacity; SD = standard deviation; FEV1 = forced expiratory volume in 1 second; TLC = total lung capacity; DLCO = diffusion capacity for carbon monoxide; SHAQ = Scleroderma Health Assessment Questionnaire